期刊文献+

胶质瘤1p/19q联合缺失特征分析 被引量:2

Analysis of 1p/19q Codeletion in Gliomas:Report of 63 Cases
下载PDF
导出
摘要 目的研究胶质瘤中1p/19q联合缺失与患者临床特征及O6-甲基鸟嘌呤-DNA甲基转移酶(O6-methylguanine-DNA methyltransferase,MGMT)表达的关系。方法使用荧光原位杂交技术,对中山大学附属肿瘤医院2009年3月至2011年3月的63例手术确诊胶质瘤标本进行1p/19q联合缺失检测,利用统计学方法分析1p/19q联合缺失患者与无联合缺失患者在性别、年龄、部位、病理类型及MGMT表达状态是否有差异。结果全组63例患者,男38例,女25例,年龄(41.7±15.3)岁。其中,16例(25.4%)存在1p/19q联合缺失。1p/19q联合缺失患者与无联合缺失患者在性别、年龄及肿瘤部位间的差异无统计学意义。各病理类型1p/19q联合缺失的比例从高到低依次为少突胶质细胞瘤(9/16)、间变性少突胶质细胞瘤(3/8)、星形细胞瘤(2/10)、间变性星形细胞瘤(1/6)及胶质母细胞瘤(1/21),其差异有统计学意义(P<0.01)。在全组63例胶质瘤及25例含少突成分胶质瘤中,MGMT阳性肿瘤1p/19q联合缺失比例与MGMT阴性组间的差异皆无统计学意义。结论 1p/19q联合缺失主要与胶质瘤的病理类型有关,含少突成分胶质瘤中1p/19q联合缺失比例较高。1p/19q联合缺失可作为少突胶质细胞瘤病理诊断的重要参考指标。 Objective To detect 1p/19q codeletion in patients with gliomas and investigate the relationship between 1p/19q codeletion and other clinical features including age, sex, location of tumors and the expression of 06- methylguanine-DNA methyhransferase (MGMT). Methods Fluorescence in situ hybridization (FISH) was used to detect 1p/19q codeletion in 63 cases with pathologically confirmed gliomas in Sun Yat-sen University from March 2009 to March. Clinical data were retrospectively reviewed. The relationship between 1p/19q codeletion and other clinical features including age, sex, location of tumors and the expression of MGMT was analyzed. Results Among 63 patients, 38 were male and 25 were female. The mean age of patients was 41.7 years. Codeltion of 1p/19q was detected in 16 cases (25.4%). There were no statistical differences in sex, age and tumor location between glioma patients with and without 1p/19q codeletion. Codeletion of 1p/19q, in an descend order, was detected in oligodendrogliomas (9/16), anaplastic oligodendrogliomas (3/8), astrocytomas (2/10), anaplastic astrocytomas (1/6) and glioblastoma muhiforme (1/21). There were statistical differences in the distribution of 1p/19q in different pathological types (P〈 0.01 ). Among 63 cases, 34 were MGMT- positive and 29 were MGMT-negative. No statistical differences of status of 1p and 19q codeletion were found between MGMT-positive and-negative tumors. Conclusions 1p/19q codeletion is associated with oligodendroglial tumors and is a useful marker for pathological diagnosis.
出处 《中国神经精神疾病杂志》 CAS CSCD 北大核心 2011年第8期490-494,共5页 Chinese Journal of Nervous and Mental Diseases
关键词 胶质瘤1p/19q联合缺失MGMT病理 Glioma 1p/19q codeletion MGMT Pathology
  • 相关文献

参考文献14

  • 1Bourne TD, Scbiff D. Update on molecular findings, management and outcome in low-grade gliornas[J]. Nat Rev Neurol, 2010,6(12) : 695-701.
  • 2Hofer S, Lassman AB. Molecular markers in gliomas : impact for the clinician [ J ]. Target Oncol, 2010,5 ( 3 ) : 201-210.
  • 3Woehrer A, Sander P, Haberler C, et al. FISH-based detection of lp 19q codeletion in oligodendroglial tumors: procedures and protocols for neuropatbologieal practice-a publication under the auspices of the Research Committee of the European Confederation of Neuropathological Societies[J].Clin Neuropathol, 2011,30 (2) :47-55.
  • 4Ducray F, E1 Hallani S, Idbaih A. Diagnostic and prognostic markers in gliomas [ J ]. Curr Opin Oncol, 2009,21 (6): 537-542.
  • 5Reifenberger J, Reifenberger G, Liu L, et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and lp[J]. Am J Pathol, 1994,145 (5) : 1175- 1190.
  • 6Bromberg JE, van den Bent MJ. Oligodendrogliomas: molecular biology and treatment[J]. Oncologist, 2009,14(2) : 155-163.
  • 7Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas[J]. J Natl Cancer Inst, 1998, 90(19) : 1473-1479.
  • 8Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, lp and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study [ J ]. J Clin Oncol, 2006,24 (29) : 4746-4753.
  • 9张俊平,魏大年,史泓浏,岳伟英,于春江,陈忠平.体外药敏试验及化疗耐药和敏感分子特征指导的恶性脑胶质瘤临床个体化化疗研究[J].中国神经精神疾病杂志,2009,35(8):476-480. 被引量:7
  • 10Weller M, Stupp R, Reifenberger G, et al. MGMT promoter metbylation in malignant gliomas: ready for personalized medi- cine? [J] Nat Rev Neural, 2010,6(1) :39-51.

二级参考文献30

  • 1何杰,郑声琴,乔颖娟,姚青,郭庆明,魏晓莹,黄培林.少突胶质细胞肿瘤染色体1p、19q和10q杂合性缺失与临床预后的关系[J].临床与实验病理学杂志,2006,22(4):444-448. 被引量:10
  • 2张淑坤,卢德宏,朴月善,蔡彦宁,徐庆中.即时荧光定量PCR微卫星分析技术检测少突胶质细胞肿瘤染色体1p/19q杂合性缺失[J].中华病理学杂志,2006,35(12):731-734. 被引量:9
  • 3Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma[ J]. N Engl J Med, 2005, 352(10) :997 - 1003.
  • 4Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis[J]. Clin Cancer Res,2001,7(4) :839 -845.
  • 5Chen ZP, Yarosh D, Garcia Y, et al. Relationship between O^6- methylguanine-DNA methyhransferase levels and clinical response induced by chloroethylnitrosourea therapy in glioma patients[ J]. Can J Neurol Sci, 1999, 26(2) : 104 -109.
  • 6Bower M, Newlands ES, Bleehen NM, et al. Muhicentre CRC phase Ⅱ trial of temozolomide in recurrent or progressive high- grade glioma[ J]. Cancer Chemother Pharmacol, 1997, 40 (6) : 484 - 488.
  • 7Sanson M, Ameri A, Monjour A, et al. Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase Ⅱ study[J]. Eur J Cancer, 1996, 32A(13) : 2229 - 2235.
  • 8Silber JR, Bobola MS, Ghatan S, et al. O^6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics [ J ]. Cancer Res, 1998,58 (5) : 1068 - 1073.
  • 9Cairncross G, Berkey B, Shaw E, et al. Phase Ⅲ trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402 [ J ]. J Clin Oncol, 2006,24 (18) :2707 -2714.
  • 10Van den Bent M J, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase Ⅲ trial [J]. J Clin Oncol, 2006, 24(18) :2715 -2722.

共引文献10

同被引文献49

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部